Personalized Radiation Oncology: Epidermal Growth Factor Receptor and Other Receptor Tyrosine Kinase Inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Radiotherapy Research

Background:

• Receptor tyrosine kinases (RTK) are investigated as molecular biomarkers in radiation oncology.
• Epidermal growth factor receptor (EGFR) plays a key role in patient prognosis and tumor radioresistance.
• EGFR signaling is implicated in tumor cell repopulation between radiotherapy fractions.

Purpose of the Study:

• To evaluate molecular biomarkers for predicting treatment decisions in radiation oncology.
• To explore the role of RTKs, including EGFR, c-Met, and IGF-1R, in tumor radioresistance.
• To identify biomarkers for selecting patients for targeted therapies and adaptive radiotherapy.

Main Methods:

• Review of preclinical and clinical studies on molecular biomarkers in radiation oncology.
• Analysis of data on EGFR's role in radiotherapy prognosis and radioresistance.
• Investigation of other RTKs like c-Met and IGF-1R in tumor radioresistance.

Main Results:

• EGFR is a significant factor in radiotherapy prognosis and radioresistance, particularly in tumor cell repopulation.
• Monoclonal antibodies targeting EGFR show potential in improving tumor control but exhibit heterogeneous effects.
• Other RTKs, including c-Met and IGF-1R, are also implicated in tumor radioresistance.

Conclusions:

• Biomarkers are essential for patient selection in molecular targeting approaches combined with radiotherapy.
• Further studies are required to evaluate adaptive radiotherapy strategies based on patient biomarkers.
• Personalized radiotherapy approaches, including dose and target volume adaptation, may benefit selected patients.